Skip to main content

Table 3 Baseline measures of osteoarthritis and related impairment.

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

Variable

Sequence A SAMe – Celecoxib (N = 28)

Sequence B Celecoxib – SAMe (N = 29)

 

N (%)

N (%)

Tenderness in Knee*

None

5 (18.5%)

6 (20.7%)

Slight

9 (33.3%)

7 (24.1%)

Moderate

13 (48.1%)

14 (48.3%)

Severe

0 (0.0%)

2 (6.9%)

Swelling in Knee*

None

15 (55.6%)

6 (20.7%)

Slight

10 (37.0%)

17 (58.6%)

Moderate

2 (7.4%)

6 (20.7%)

Fluid in Knee Joint*

None

22 (81.5%)

20 (69.0%)

Slight

3 (11.1%)

7 (24.1%)

Moderate

2 (7.4%)

2 (6.9%)

Redness in Knee*

0 (0.0%)

1 (3.4%)

Walking Distance**

<1 block without pain

3 (10.7%)

3 (10.3%)

<1 block with pain

1 (3.6%)

4 (13.8%)

<1 mile without pain

1 (3.6%)

1 (3.4%)

<1 mile with pain

6 (21.4%)

7 (24.1%)

>1 mile without pain

6 (21.4%)

4 (13.8%)

>1 mile with pain

12 (42.9%)

13 (44.8%)

Basic ADL – Need Assistance with

Dressing

1 (3.6%)

0 (0.0%)

Transferring

0 (0.0%)

0 (0.0%)

Bathing

0 (0.0%)

0 (0.0%)

Toileting

0 (0.0%)

0 (0.0%)

Advanced ADL – Difficulty with

Light housework

1 (3.6%)

4 (13.8%)

Heavy housework

9 (32.1%)

16 (55.2%)

Stooping / crouching

26 (92.9%)

27 (93.1%)

Getting in/out of car

17 (60.7%)

18 (62.1%)

  1. * One patient in Sequence A had missing data. ** Multiple responses per patient were allowed. There were no statistically significant differences between the two sequences.